1. Home
  2. BWMX vs GYRE Comparison

BWMX vs GYRE Comparison

Compare BWMX & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Betterware de Mexico S.A.P.I. de C.V.

BWMX

Betterware de Mexico S.A.P.I. de C.V.

HOLD

Current Price

$17.19

Market Cap

621.6M

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$4.38

Market Cap

625.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BWMX
GYRE
Founded
1995
2002
Country
Mexico
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
621.6M
625.6M
IPO Year
2019
2004

Fundamental Metrics

Financial Performance
Metric
BWMX
GYRE
Price
$17.19
$4.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
★ $29.20
$18.67
AVG Volume (30 Days)
59.4K
★ 133.8K
Earning Date
10-22-2026
11-17-2026
Dividend Yield
★ 6.67%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $275,000.00
Revenue This Year
$25.39
N/A
Revenue Next Year
$14.43
$27.49
P/E Ratio
$12.54
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$13.41
$4.27
52 Week High
$19.79
$9.14

Technical Indicators

Market Signals
Indicator
BWMX
GYRE
Relative Strength Index (RSI) 59.11 29.97
Support Level $15.62 N/A
Resistance Level $19.22 $7.44
Average True Range (ATR) 0.55 0.50
MACD 0.13 -0.18
Stochastic Oscillator 86.40 6.17

Price Performance

Historical Comparison
BWMX
GYRE

About BWMX Betterware de Mexico S.A.P.I. de C.V.

Betterware de Mexico SAPI de CV is a company in the consumer product goods industry focused on home organization and beauty and personal care products, commercialized through person-to-person selling. The Group operates through two segments: Home organization under the Betterware brand, including kitchen and food preservation, home solutions, bathroom, laundry & cleaning, tech and mobility, bedroom and wellness. Products are sold through catalogues and distributed through distributors and associates. The Beauty and personal care (B&PC) segment under the JAFRA brand, which generates maximum revenue, includes fragrance, color, skin care and toiletries, distributed through leaders and consultants. The Group operates in Mexico, which generates maximum revenue, the United States and Latam.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: